BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 22448649)

  • 1. Prostate-specific antigen testing in older men in the USA: data from the behavioral risk factor surveillance system.
    Scosyrev E; Wu G; Golijanin D; Messing E
    BJU Int; 2012 Nov; 110(10):1485-90. PubMed ID: 22448649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation.
    Cohn JA; Wang CE; Lakeman JC; Silverstein JC; Brendler CB; Novakovic KR; McGuire MS; Helfand BT
    Urol Oncol; 2014 Jan; 32(1):41.e23-30. PubMed ID: 23911680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral associations between prostate and colon cancer screening.
    Carlos RC; Underwood W; Fendrick AM; Bernstein SJ
    J Am Coll Surg; 2005 Feb; 200(2):216-23. PubMed ID: 15664097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen testing: men's responses to 2012 recommendation against screening.
    Squiers LB; Bann CM; Dolina SE; Tzeng J; McCormack L; Kamerow D
    Am J Prev Med; 2013 Aug; 45(2):182-9. PubMed ID: 23867025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.
    Moyer VA;
    Ann Intern Med; 2012 Jul; 157(2):120-34. PubMed ID: 22801674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer screening in men 75 years old or older: an assessment of self-reported health status and life expectancy.
    Hoffman KE; Nguyen PL; Ng AK; D'Amico AV
    J Urol; 2010 May; 183(5):1798-802. PubMed ID: 20299039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decrease in Prostate Cancer Testing Following the US Preventive Services Task Force (USPSTF) Recommendations.
    Li J; Berkowitz Z; Hall IJ
    J Am Board Fam Med; 2015; 28(4):491-3. PubMed ID: 26152440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75.
    Caire AA; Sun L; Robertson CN; Polascik TJ; Maloney KE; George DJ; Price MM; Stackhouse DA; Lack BD; Albala DM; Moul JW
    Urology; 2010 May; 75(5):1122-7. PubMed ID: 19815259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of prostate specific antigen testing for prostate cancer in elderly men.
    Dyche DJ; Ness J; West M; Allareddy V; Konety BR
    J Urol; 2006 Jun; 175(6):2078-82. PubMed ID: 16697807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the 2008 U.S. Preventative Services Task Force recommendation on frequency of prostate-specific antigen screening in older men.
    Lee SY; Friderici J; Stefan MS; Rothberg MB
    J Am Geriatr Soc; 2014 Oct; 62(10):1912-5. PubMed ID: 25284269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen screening for prostate cancer in older men in the United States of America.
    Black A; Berg CD
    Gerontology; 2012; 58(4):331-6. PubMed ID: 22343605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the 2012 United States Preventive Services Task Force statement on prostate-specific antigen screening: analysis of urologic and primary care practices.
    Perez TY; Danzig MR; Ghandour RA; Badani KK; Benson MC; McKiernan JM
    Urology; 2015 Jan; 85(1):85-9. PubMed ID: 25440819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
    Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
    BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practitioner-level determinants of inappropriate prostate-specific antigen screening.
    Kerfoot BP; Holmberg EF; Lawler EV; Krupat E; Conlin PR
    Arch Intern Med; 2007 Jul; 167(13):1367-72. PubMed ID: 17620529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.
    Welch HG; Schwartz LM; Woloshin S
    J Natl Cancer Inst; 2005 Aug; 97(15):1132-7. PubMed ID: 16077071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. State-specific prevalence of selected chronic disease-related characteristics--Behavioral Risk Factor Surveillance System, 2001.
    Ahluwalia IB; Mack KA; Murphy W; Mokdad AH; Bales VS
    MMWR Surveill Summ; 2003 Aug; 52(8):1-80. PubMed ID: 14532868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surveillance of certain health behaviors and conditions among states and selected local areas--Behavioral Risk Factor Surveillance System (BRFSS), United States, 2006.
    Kilmer G; Roberts H; Hughes E; Li Y; Valluru B; Fan A; Giles W; Mokdad A; Jiles R;
    MMWR Surveill Summ; 2008 Aug; 57(7):1-188. PubMed ID: 18701879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.
    Drazer MW; Huo D; Eggener SE
    J Clin Oncol; 2015 Aug; 33(22):2416-23. PubMed ID: 26056181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era.
    Welch HG; Fisher ES; Gottlieb DJ; Barry MJ
    J Natl Cancer Inst; 2007 Sep; 99(18):1395-400. PubMed ID: 17848671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The distribution of serum prostate-specific antigen levels among American men: implications for prostate cancer prevalence and screening.
    Porter MP; Stanford JL; Lange PH
    Prostate; 2006 Jul; 66(10):1044-51. PubMed ID: 16598738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.